- Home
- RMM vs PGEN Comparison
RMM vs PGEN Comparison
Compare RMM & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMM
- PGEN
- Stock Information
- Founded
- RMM 2019
- PGEN 1998
- Country
- RMM United States
- PGEN United States
- Employees
- RMM N/A
- PGEN N/A
- Industry
- RMM Trusts Except Educational Religious and Charitable
- PGEN Biotechnology: Pharmaceutical Preparations
- Sector
- RMM Finance
- PGEN Health Care
- Exchange
- RMM Nasdaq
- PGEN Nasdaq
- Market Cap
- RMM 303.8M
- PGEN 292.6M
- IPO Year
- RMM N/A
- PGEN N/A
- Fundamental
- Price
- RMM $15.80
- PGEN $0.91
- Analyst Decision
- RMM
- PGEN Buy
- Analyst Count
- RMM 0
- PGEN 5
- Target Price
- RMM N/A
- PGEN $7.00
- AVG Volume (30 Days)
- RMM 66.5K
- PGEN 915.1K
- Earning Date
- RMM 01-01-0001
- PGEN 11-14-2024
- Dividend Yield
- RMM 7.33%
- PGEN N/A
- EPS Growth
- RMM N/A
- PGEN N/A
- EPS
- RMM 0.96
- PGEN N/A
- Revenue
- RMM N/A
- PGEN $3,963,000.00
- Revenue This Year
- RMM N/A
- PGEN N/A
- Revenue Next Year
- RMM N/A
- PGEN $426.76
- P/E Ratio
- RMM $15.55
- PGEN N/A
- Revenue Growth
- RMM N/A
- PGEN N/A
- 52 Week Low
- RMM $12.32
- PGEN $0.77
- 52 Week High
- RMM $16.10
- PGEN $1.93
- Technical
- Relative Strength Index (RSI)
- RMM 58.53
- PGEN 51.86
- Support Level
- RMM $15.48
- PGEN $0.84
- Resistance Level
- RMM $15.92
- PGEN $0.97
- Average True Range (ATR)
- RMM 0.18
- PGEN 0.07
- MACD
- RMM 0.05
- PGEN 0.01
- Stochastic Oscillator
- RMM 82.09
- PGEN 60.39
About RMM RiverNorth Managed Duration Municipal Income Fund Inc.
RiverNorth Managed Duration Muni Inc Fd is a United States based diversified, closed-end management investment company. Its primary investment objective is current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.
About PGEN Precigen Inc.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.